Premium
Acute myeloid leukemia in the elderly (age 70 yr or older): long‐term survivors
Author(s) -
Heiblig Maël,
Elhamri Mohamed,
Le Jeune Caroline,
Laude MarieCharlotte,
Deloire Alexandre,
Wattel Eric,
Salles Gilles,
Thomas Xavier
Publication year - 2017
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12811
Subject(s) - medicine , myeloid leukemia , cohort , pediatrics , population , cohort study , chemotherapy , leukemia , survival analysis , overall survival , environmental health
Objective Little data exist regarding long‐term survival in elderly patients with acute myeloid leukemia ( AML ). Methods In view of the fact that most deaths occurred during the first 3 yr, this study examined long‐term survival in this patient population, defined as overall survival for at least 3 yr with the aim to determine the number of long‐term survivors and to identify factors that might impact on longer survival. Results The criterion for entry into this cohort was fulfilled by 57 patients among 302 seen over a 14‐yr period (19%): 12 patients who never achieved complete remission ( CR ), 21 patients who relapsed after CR achievement, and 24 patients who achieved CR and did not relapse, including three patients who died while in CR and 21 patients still alive in first CR at the time of analysis. The pretreatment prognostic importance of cytogenetics was still apparent. However, some patients with secondary AML and/or unfavorable‐risk markers belonged to long survivors. The cohort involved mainly patients treated by intensive chemotherapy, but also some patients receiving low‐intensity therapies. Conclusion Improved results should come from a better selection of patients to a more ‘personalized’ therapeutic approach combined with better supportive care assessment.